Company Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.
The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians.
Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes.
The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products.
It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 1999 |
| IPO Date | Apr 14, 2005 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 10,300 |
| CEO | Kevin Sayer |
Contact Details
Address: 6340 Sequence Drive San Diego, California 92121 United States | |
| Phone | 858 200 0200 |
| Website | dexcom.com |
Stock Details
| Ticker Symbol | DXCM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001093557 |
| CUSIP Number | 252131107 |
| ISIN Number | US2521311074 |
| Employer ID | 33-0857544 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Kevin Ronald Sayer | Executive Chairman, Chief Executive Officer and President |
| Jereme M. Sylvain CPA | Executive Vice President, Chief Financial Officer and Chief Accounting Officer |
| Jacob Steven Leach | Executive Vice President and Chief Operating Officer |
| Michael Jon Brown | Executive Vice President and Chief Legal Officer |
| Sadie M. Stern | Executive Vice President and Chief Human Resources Officer |
| Girish Naganathan | Executive Vice President and Chief Technology Officer |
| Sean Christensen | Vice President of Finance and Investor Relations |
| Matthew Dolan | Executive Vice President of Strategy, Corporate Development and Dexcom Labs |
| Leverne Marsh | Executive Vice President of Marketing |
| Donald M. Abbey | Executive Vice President of Global Business Services, IT, Quality and Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 2, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 2, 2025 | 8-K | Current Report |
| May 1, 2025 | 10-Q | Quarterly Report |
| May 1, 2025 | 8-K | Current Report |
| Apr 24, 2025 | SCHEDULE 13G/A | Filing |
| Mar 27, 2025 | ARS | Filing |
| Mar 27, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 27, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 25, 2025 | 8-K | Current Report |
| Mar 17, 2025 | 144 | Filing |